Brainstorm Cell Therapeutics (BCLI) Projected to Post Quarterly Earnings on Monday

Brainstorm Cell Therapeutics (NASDAQ:BCLI) is anticipated to post its quarterly earnings results before the market opens on Monday, March 31st. Analysts expect Brainstorm Cell Therapeutics to post earnings of ($0.49) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Brainstorm Cell Therapeutics Stock Performance

NASDAQ:BCLI opened at $1.19 on Friday. Brainstorm Cell Therapeutics has a 1 year low of $1.05 and a 1 year high of $11.25. The business has a fifty day moving average of $1.71 and a 200-day moving average of $2.03. The stock has a market cap of $6.79 million, a price-to-earnings ratio of -0.25 and a beta of 0.74.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics in a research report on Wednesday. They set a “hold” rating on the stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.